190 related articles for article (PubMed ID: 33129112)
1. Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Viteri S; d'Hondt E; Rosell R
Transl Oncol; 2021 Jan; 14(1):100887. PubMed ID: 33129112
[TBL] [Abstract][Full Text] [Related]
2. Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
Codony-Servat J; García-Roman S; Molina-Vila MÁ; Bertran-Alamillo J; Giménez-Capitán A; Viteri S; Cardona AF; D'Hondt E; Karachaliou N; Rosell R
J Thorac Oncol; 2018 Sep; 13(9):1324-1337. PubMed ID: 29751136
[TBL] [Abstract][Full Text] [Related]
3. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways.
García-Roman S; Garzón-Ibáñez M; Bertrán-Alamillo J; Jordana-Ariza N; Giménez-Capitán A; García-Peláez B; Vives-Usano M; Codony-Servat J; d'Hondt E; Rosell R; Molina-Vila MÁ
Transl Oncol; 2024 Feb; 40():101878. PubMed ID: 38183801
[TBL] [Abstract][Full Text] [Related]
4. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Hong S; Chen N; Fang W; Zhan J; Liu Q; Kang S; He X; Liu L; Zhou T; Huang J; Chen Y; Qin T; Zhang Y; Ma Y; Yang Y; Zhao Y; Huang Y; Zhang L
Oncoimmunology; 2016 Mar; 5(3):e1094598. PubMed ID: 27141355
[TBL] [Abstract][Full Text] [Related]
6. RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report.
Yan H; Zeng L; Zhang Y
Heliyon; 2024 May; 10(9):e29928. PubMed ID: 38698976
[TBL] [Abstract][Full Text] [Related]
7. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
8.
Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
11. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
12. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573
[TBL] [Abstract][Full Text] [Related]
13. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
14. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
15. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
16. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
18. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
[TBL] [Abstract][Full Text] [Related]
19. Targeting RET-rearranged non-small-cell lung cancer: future prospects.
Bronte G; Ulivi P; Verlicchi A; Cravero P; Delmonte A; Crinò L
Lung Cancer (Auckl); 2019; 10():27-36. PubMed ID: 30962732
[TBL] [Abstract][Full Text] [Related]
20. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]